Xolair was originally approved to treat asthma in 2003. It was endorsed in February of last year for those age 1 and older with IgE-mediated food allergies. (Stock Photo ) A year after the FDA blessed ...

Please provide your email address to receive an email when new articles are posted on . The campaign follows the approval of Xolair for the reduction of allergic reactions after accidental exposure.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today new positive data from Stage 2 and Stage 3 of the National Institutes ...

Roche Holdings AG (OTC:RHHBY) released data Sunday on its Stage 2 and Stage 3 of the National Institutes of Health (NIH)-sponsored phase 3 OUtMATCH study for Xolair (omalizumab) for one or more food ...

Tami McGraw used to be so allergic to red meat that even fumes from cooking might send her into anaphylactic shock. She couldn’t fry sausages for her family. She couldn’t go to cookouts with friends.

People with food allergies need to avoid the foods causing their problem, of course, but “Accidents Happen.” That’s the title of a new campaign from Xolair, the first drug approved by the FDA to treat ...

The U.S. Food and Drug Administration has approved Xolair as the first and only medicine for people with one or more food allergies after the clinical trial data for the injectable asthma medication ...

Lycia Therapeutics is banking on a $227.8 million IPO as the biotech seeks to finance its pipeline of protein degraders for autoimmune, inflammatory and allergic diseases. | Lycia Therapeutics is ...

Xolair is the only US FDA-approved medicine to reduce allergic reactions in children and adults with one or more food allergies Basel, 2 March 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today ...